India focus: Better protection for big pharma?

The last 12 months have brought a lot of change in India. First, a new government, the Bharatiya Janata Party, was voted into office in May 2014 and said straight away it would be focusing on, among other things, intellectual property.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Takeda’s China IP head: What pharma is still getting wrong

27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.

Asia

Healthcare leads sweeping AI partnership in Singapore

20 May 2026 Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.

Asia

IndiaMart v CDSCO: A test of intermediary liability

31 March 2026 The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.

More features

Takeda’s China IP head: What pharma is still getting wrong

Boehringer Ingelheim adds ex-Teva executive to patent team

AI, anxiety, and antibodies: The issues dominating life sciences

Lupin scores another win in kidney drug dispute

Battle over inhaler shape ends badly for Boehringer

Healthcare leads sweeping AI partnership in Singapore

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme

AbbVie’s trade secret suit against a Chinese rival gets green light

India focus: Better protection for big pharma?

More on this story

Editor's picks

Editor's picks

More features